tirzepatide effect on blood pressure Will Lower Pressure? UK Clinical Evidence Understanding Tirzepatide: The Dual-Action Breakthrough

Secondary y-axis represents recombination fraction from 1000 Genomes Project and horizontal dashed line highlights the association threshold for significance (p=510 8 )

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss in clinical trials

Administered once weekly via subcutaneous injection, Ozempic is typically initiated at 0.25 mg weekly for four weeks, then increased to 0.5 mg weekly

Preliminary research suggests that allulose may influence the secretion or activity of endogenous GLP-1, potentially offering complementary benefits when used alongside GLP-1-based therapies

Some individuals experience minor improvements in their dizziness and weakness

*T de student= nivel de significancia**, HB=hemoglobina, HTO= hematocrito, TGC= triglicridos, Na= sodio, K= potasio, Ca= calcio, P= potasio